MISSISSAUGA, Ontario – MedX Health Corp. (TSXV: MDX), a global leader in teledermatology, is excited to announce the successful completion of its pilot project with Health Partners, a prominent UK-based corporate health and primary care services provider. This collaboration marks a significant step forward in proactive healthcare management, bringing MedX’s innovative teledermatology solutions to Health Partners’ extensive client network. The partnership is set to roll out a comprehensive skin cancer screening service to Health Partners’ corporate clients, focusing on preventative health strategies and early detection.
Health Partners Group Limited, a respected private entity in the UK’s health sector, offers a wide array of services spanning corporate health, treatment, and primary care. With over 1,000 employees and a broad reach across the UK and the Republic of Ireland, Health Partners serves a diverse clientele, including corporations, government bodies, insurers, and individuals. Their adoption of MedX’s teledermatology platform underscores a commitment to leveraging cutting-edge technology for superior patient care.
The urgency for enhanced skin cancer screening is underscored by alarming statistics in the UK, where over 220,000 new cases are diagnosed annually, and incidence rates continue to climb. Outdoor workers, particularly vulnerable due to significantly higher sun exposure, face a 60% greater risk of developing this prevalent cancer, according to the UK Cancer Alliance. The COVID-19 pandemic further exacerbated the situation, causing disruptions in routine healthcare and early detection services for melanoma, the most lethal form of skin cancer. Early detection is critical; survival rates dramatically improve from 30% for Stage 4 melanoma to 99% for Stage 1-2 diagnoses, as reported by Cancer Research UK.
MedX’s SIAscope® devices and DermSecure® platform offer a solution by enabling efficient and accessible dermatologist-assessed skin cancer screenings directly in the workplace. Mike Druhan, President of Dermatology Services at MedX, highlighted the strategic advantage of Health Partners in delivering this service to at-risk individuals as part of their routine employee health assessments. The successful pilot project has demonstrated the seamless integration and effectiveness of this potentially life-saving service.
Andrew Noble, Managing Director at Health Partners, emphasized their clinical team’s dedication to adopting leading technological innovations to benefit their extensive patient base of over two million. “The pilot clearly illustrated MedX’s advanced skin assessment technology allows our dermatologists to perform rapid and accurate remote evaluations of pigmented lesions and moles. We are proud to collaborate with MedX to introduce this groundbreaking service to our clients, enhancing our commitment to proactive and impactful healthcare solutions.”
About Health Partners Group Ltd.:
Based in East Sussex, UK, Health Partners is a premier health and wellbeing organization, delivering a full spectrum of corporate health, treatment, and primary care services. Their client base includes corporations, government agencies, insurers, health trusts, pension funds, and families. Health Partners combines expert clinical services with an innovative platform to deliver customized health programs aimed at improving wellbeing and performance. Holding numerous prestigious accreditations including ISO27001 and CQC, Health Partners is recognized as a leader in UK corporate health, serving over two million individuals across various industries throughout the UK and the Republic of Ireland. For more information, please visit: http://www.healthpartnersgroup.com
About MedX Health Corp.:
MedX Health Corp., headquartered in Ontario, Canada, is a pioneering medical device and software company specializing in skin health. Their DermSecure® telemedicine platform features SIAscopy® technology, also integrated into their SIAMETRICS®, SIMSYS®, and MoleMate® products, manufactured in their ISO 13485 certified facility. MedX’s SIAscopy® technology employs handheld devices using patented light-based technology to non-invasively assess suspicious moles and lesions, capturing real-time images for rapid evaluation by physicians and dermatologists. Cleared by global regulatory bodies including Health Canada, FDA, and CE, MedX products are available in multiple markets. Visit https://medxhealth.com for more information.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This Media Release may contain forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties.
Contacts
Bill Mitoulas, Investor Relations
MedX Health Corp.
[email protected]
+1-416-479-9547
